Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-24

Study Completion Date

2020-11-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Randomized, Double-Blind, Placebo-Controlled, Parallel Group Clinical Study of ICP-332 in Healthy Subjects

NCT05399030

Healthy Subjects

COMPLETED PHASE1

A Clinical Study of MK-7962 in Healthy Chinese Participants (MK-7962-021)

NCT06843460

Healthy

COMPLETED PHASE1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects

NCT07057726

Safety and Tolerability in Healthy Volunteers

ENROLLING_BY_INVITATION PHASE1

Pharmacokinetics and Safety in Healthy Volunteers

NCT03917628

Healthy

COMPLETED PHASE1

The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

NCT04880512

Healthy Subjects

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase 1, First-in-Human, Randomized, Double-blinded, Placebo-Controlled, Single Ascending Dose Study of SCTA01(Anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.

Dose escalation will be guided by a safety review of clinical signs and symptoms, adverse events (AEs), and laboratory results of the prior dose cohort.

An Interim analysis will be performed after Day 28 post-dose for the last dose cohort for review.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Disease 2019(COVID-19)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

anti-SARS-CoV-2 monoclonal antibody(SCTA01)

SCTA01: single dose on Day0

Group Type EXPERIMENTAL

SCTA01

Intervention Type BIOLOGICAL

recombinant humanized anti-SARS-CoV-2 monoclonal antibody

Placebo

Placebo: single dose on Day0

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SCTA01

recombinant humanized anti-SARS-CoV-2 monoclonal antibody

Intervention Type BIOLOGICAL

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide written informed consent
* Males or females. Aged ≥ 18 years old
* Body mass index (BMI) between 18.0 and 26.0 kg/m2
* Normal or abnormal but non-clinical significant physical examination, vital signs, 12-ECG and chest CT, etc
* No plan of pregnancy and being willing to use effective contraceptive measures (including partner) from informed consent to 6 months after administration of SCTA01/placebo (abstinence，sterilization operation，contraceptive barrier，acyeterion , etc.)

Exclusion Criteria

* Having a history of severe allergy, such as severe allergic reactions, urticaria, angioedema;
* Having one of the following evidence on SARS-CoV-2 infection(previous tests were accepted)：

* SARS-CoV-2 positive: reverse transcription-polymerase chain reaction (RT-PCR) and/or next generation sequencing (NGS)
* Previous viral gene sequencing showed high homology with the known SARS-CoV-2
* Positive specific antibody IgM or IgG against serum SARS-CoV-2
* Having a history of severe allergies, such as severe allergic reactions, urticaria, angioedema;
* Having active infection or fever before to enrollment(≥ 37.3℃)
* Having primary disease in main organs, such as heart, lung, kidney, liver, nervous system, gastrointestinal system dysfunction, history of thrombocytopenia or abnormal bleeding
* Suffering from autoimmune diseases or a history of autoimmune diseases (such as systemic lupus erythematosus, thyroid Inflammation, vasculitis, etc.)
* Within 7 days prior to the first dose of SCTA01/placebo, subject has received any prescription drugs, non-prescription drugs, Chinese herbal medicines and health products
* Within 3 months prior to the first dose of SCTA01/placebo, subjects who participated in other clinical study, or remaining in the elimination period of the drug (within 5 half-lives) before treatment
* Within 30 days prior to the first dose of SCTA01/placebo, subjects who have received vaccine
* Within 3 months prior to the first dose of SCTA01/placebo, subjects who have received blood product treatment or blood donation and hemorrhage ≥400mL, or subjects who has a blood donation plan within 3 months after treatment
* Within 6 months prior to the first dose of SCTA01/placebo, subjects who have received major surgery, or has surgery plan during clinical trail
* Pregnant or lactating women or positive β-HCG, has plan of pregnancy from informed consent signed to 6 months after administration of SCTA01/placebo
* Positive of anti-HIV, TP-Ab, anti-HCV, anti-HBV
* Having a history of epilepsy
* Having a history of malignancies
* Within 3 months prior to screening, sujects who have drunk more than 14 standard units (1 standard unit contains 14g alcohol, such as 360mL beer, 45mL spirits with 40% alcohol or 150mL wine), or positive of alcohol breath test
* Within 3 months prior to screening, subjects who smoked more than 5 cigarettes per day, do not accept smoking cessation during the study
* Having a history of drug addiction and drug abuse; or who have a positive urine test result for drug abuse; or cannot guarantee that they will not abuse drugs during the study
* Subjects who are not able to follow the plan to complete the study
* Subjects who are not considered suitable for the study by investigators

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes